Optimizing Treatment Strategies Using Nucleos(t)ide Analogues for Patients with Chronic Hepatitis B
(Antivirale behandeling van chronische hepatitis B: het optimaliseren van behandelstrategieën met nucleos(t)ideanalogen)
2010-11-24
Doctoral Thesis
| Related Files |
|---|
View PDF Version
(101124_Reijnders,, Jurrien Gerben Peter.pdf, 0.9MB) |
|
View PDF Version
(Jurrien stellingen.pdf, 0.0MB) |
Hepatitis B infection has a complex natural history and causes a wide spectrum of disease. Although effective vaccines are available, universal vaccination has yet not been reached. Currently, an estimated 350 million people are chronically infected, and 0.5-1.2 million subjects die every year due to long-term sequalae of hepatitis B related chronic liver disease, such as liver cirrhosis and hepatocellular carcinoma Despite evidence-based treatment guidelines areas of disagreement on the management of chronic hepatitis B virus (HBV) infection still exist. With the currently approved treatment options the ultimate goal is to prevent the development of long-term sequelae of chronic liver disease. Current treatment strategies consist of either therapies with fi nite duration that aims to achieve sustained off-treatment remission (interferon-based therapy), or long-term therapy that aims to maintain on-treatment response (nucleos(t)ide analogues).
Erasmus MC Rotterdam,
Nederlandse Vereniging voor Gastroenterologie,
Novartis,
Gilead Sciences,
Bristol-Myers Squibb,
J.E. Jurriaanse Stichting
- patient
- hepatitis
- treatment
- hepatitis b
- therapy
- hbeag
- resistance
- response
- study
- baseline
- level
- nucleo
- hbv dna
- hbsag
- virologic response
- month
- hbeag seroconversion
- virologic
- seroconversion
- follow-up
